EAN News Newsletter of the EPIET Alumni Network

Total Page:16

File Type:pdf, Size:1020Kb

EAN News Newsletter of the EPIET Alumni Network EAN News Newsletter of the EPIET Alumni Network www.epietalum.net Special issue: Ebola February 2015 Winter newsletter ‘P(PE)raying Circle’, by Nadine Zeitlmann (C2013) Editorial Board Dear EAN members, experiences of setting up a mobile President lab in Guinea; Sophie Newitt (UK Happy New Year! We begin this year’s FETP C2013) and Jorge del Diego Naomi Boxall EAN newsletter series with a special share a New Year’s wish with us from issue focussing on the Ebola outbreak the field; and Appi Epi features useful Vice-President in West Africa (already over a year Ebola-related online resources. Ricardo Mexia since the first case!). Also in this issue: intros from our Chikwe Ihekweazu (EPIET C9) gives two new board members, Ricardo Treasurer a longer term perspective on how and Katherina; “Where Are You Katherina Zakikhany best to respond to the outbreak. Now?” features from three recently Anthropologist Annie Wilkinson graduated C2012 fellows; ESCAIDE introduces the Ebola Response experiences from this year’s EAN Treasurer Anthropology Platform, an online travel grant awardees – and last but Javiera Rebolledo resource for field responders to help not least, an introduction to the better understand and utilise the brand new EAN website! Secretary cultural contexts where they are working to improve control measures. Enjoy the read and all the best for Georgia Ladbury 2015, C2013 fellows recently back from The EAN Board Secretary missions reflect on their experiences and Maria Keramarou both in the field and returning home; Zuzana Klochanova & Suzan Trienekens Zoltan Kis (EUPHEM C2013) shares his Editor & Designer Page 1 Beyond epicurves - Chikwe Ihekweazu Do we have a broader responsibility to Back in Geneva for a de-brief with WHO, I tried public health as field epidemiologists? to ask more experienced colleagues how they managed to deal with the pain of leaving I remember the adrenaline rush when the first outbreak situations when the outbreak was opportunity to participate in an Ebola outbreak controlled. It was clear to me that while we came my way in 2004, as an EPIET fellow. A more may have helped put out one fire; we had not experienced colleague who had been chosen influenced the circumstances that led to the for the mission had to cancel at the last minute fire. Very early in my career, I felt the limitations for personal reasons and the opportunity came of the scope of field epidemiology. I thought: my way. It was the first of several missions that There must be more that we can do. I undertook for the World Health Organisation’s (WHO) Global Outbreak Alert and Response Ten years later, I am in Liberia as part of the Network. The outbreak was in Yambio, South huge response to the largest Ebola outbreak Sudan, one of the poorest countries in the world ever. As always there are many competent which was then just coming out of a protracted and well-meaning experts, which is exactly crisis. The location of the outbreak was not far what the situation has been calling for. Almost from the site where the first Ebola outbreak was every international NGO is in Liberia, Guinea reported in 1976. and Sierra Leone. For the first time, in the early weeks of 2015, the epicurve is beginning to I was lucky to work with an extremely head south. experienced and supportive team from the WHO, the US Centers for Disease Control (CDC) While the outbreak is by no means over, there and Medecins Sans Frontieres (MSF). I learnt is a feeling in the field that we are beginning to a lot from these colleagues in an intensive get the scale of response that is commensurate outbreak response that lasted about four with the size of this large outbreak. Over dinner weeks. Luckily, the outbreak was controlled; and coffee, I can’t help but listen to some of we ended up with a total of 17 cases, including the conversations. There is a growing feeling of seven deaths. quiet optimism, and when the outbreak is over there will be many more colleagues that will in At the end of that outbreak, WHO said, in a the next few months add an important line to statement still on their website (http://www. their resumes. who.int/mediacentre/news/releases/2004/ Yes, I am confident that if we continue working pr54/en) that: “The lessons we learned in as hard as we are at the moment, we will Yambio from this outbreak will strengthen eventually control this outbreak. Then, most of our responses to future outbreaks,” ... “The us will go home. Some of us will proceed to the Yambio experience has proven the value next crisis and others will go back to some of of rapid outbreak detection, local response those old-school, less glamorous public health capacities, active community involvement, and challenges like tuberculosis. Don’t expect an the coordination of specialized international international mobilisation for that. assistance to the outbreak’s containment”. So, would we have completed our jobs as field After that outbreak, the team felt a sense epidemiologists when this outbreak is finally of accomplishment, which I shared. We had under control? Since most of us as are not part probably helped save hundreds if not thousands of the decision making processes that relate to of lives. But I could not get South Sudan off my economic development in countries like Liberia, mind. I met a young man during that outbreak the natural answer would be “yes”. But can we – a “survivor”, with whom I kept in touch for a continue with this same paradigm in 2015? Can while. He had joined our social mobilization we really afford to go back to work – and forget team and supported our response. I felt obliged Liberia? Can we leave it to the bureaucrats at to help him get back to a “normal” life, and I did the World Bank or IMF as has been the case in this for a while. But, with time, I “let go”. the past? Page 2 Beyond epicurves - Chikwe Ihekweazu This time, things have to be different – we just from the HIV/AIDS global epidemic that robust cannot afford to casually go back to the status health systems are critical in mounting and quo. We have to raise our collective voices sustaining a vigorous response to an emerging about the situation in the clinics that we visited disease threat. This 2014 Ebola outbreak for “assessments” and the conditions in the provides a unique opportunity to rebuild schools from which we recruited teachers as and strengthen health systems and should “social mobilisers”. The conditions in the slums serve as an instigator for a much more robust that we drove past in our white jeeps are not investment in public health. “normal” for Liberia! They cannot be “normal” in any country. It really does not matter how Being part of this response is a rare privilege. much airport screening we do, humanity stands It is not one that can be completed with a no chance against viruses if people live in the “mission report”. If the over 1000 international squalor of West Point. colleagues that have participated in this response change their views on public health More than ever before there is a possibility that as our collective responsibility, we may have we can engage the attention of the world to a small chance of really changing the way we call for collective action to force the change think about intervention field epidemiology. that needs to happen in places like Liberia, The one thing that we can be absolutely sure which the outbreak has brought to the world’s of is that there will be another large outbreak attention. As epidemiologists that have spent somewhere in the world in the next few years. months in the field, we have a moral obligation It really is our collective choice to either learn to lend our voices to the broader struggle. We from history or to keep doing things the cannot and should not look away. same way we always have. Granted, working in partnership for development is a lot more We must raise our voices and share our complicated than “outbreak control” – but this experience and call our governments to action. really is the only sustainable way forward. We have a responsibility to try to influence the broader public health agenda beyond the The choice is ours. technical aspects of our work. We have learnt The Ebola Response Anthropology Platform Annie Wilkinson is a social anthropologist at on the ‘ignorance’ and ‘superstition’ of local the UK Institute of Development Studies and populations, supposedly evidenced by member of the Ebola Response Anthropol- Ebola denial and preference for ‘traditional’ treatments and burials. Relationships between ogy Platform. Her current research focuses local populations and response partners were on health systems, after a PhD investigating clearly problematic. However, such ‘culturalist’ health seeking and diagnosis of Lassa fever in interpretations are misleading as they deny Sierra Leone. the validity of local people’s logics and perspectives, including those rooted in the The Ebola Response Anthropology Platform experience of inadequate health systems and was set up out of a concern that the social of governments proven not to act in people’s and political dimensions of the West African interest. In addition, the top-down and Ebola epidemic were being overlooked and medicalised approaches which have dominated misunderstood. From early on, conventional the response to date have too often excluded tools of containment for Ebola were failing as local people from meaningful involvement in public health teams were met with fear and efforts managing the epidemic and from decisions over to isolate patients, quarantine households their health, or the burial of family members.
Recommended publications
  • WHO Launches Hub in Berlin to Help Prevent Future Pandemics 1 September 2021
    WHO launches hub in Berlin to help prevent future pandemics 1 September 2021 The COVID-19 pandemic "has taught the world many painful lessons," Tedros said. "One of the most clear is the need for new, powerful systems and tools for global surveillance to collect, analyze and disseminate data on outbreaks with the potential to become epidemics and pandemics." "Viruses move fast but data can move even faster," Tedros said. He added that the new center is one response to recommendations on what can be done to keep the world safer in the future, "filling a gap in the world's defenses." Tedros Adhanom Ghebreyesus, right, Director-General of the World Health Organization (WHO), and German Chancellor Angela Merkel, left, attend the inauguration ceremony of the 'WHO Hub For Pandemic And Epidemic Intelligence' at the Langenbeck-Virchow building in Berlin, Germany, Wednesday, Sept. 1, 2021. Credit: AP Photo/Michael Sohn, pool The World Health Organization on Wednesday inaugurated a new "hub" in Berlin that aims to help prepare the globe better to prevent future pandemics. Tedros Adhanom Ghebreyesus, right, Director-General of the World Health Organization (WHO), and German WHO Director-General Tedros Adhanom Chancellor Angela Merkel, left, attend the inauguration Ghebreyesus and German Chancellor Angela ceremony of the 'WHO Hub For Pandemic And Epidemic Merkel cut the ribbon to launch the new WHO Hub Intelligence' at the Langenbeck-Virchow building in for Pandemic and Epidemic Intelligence. WHO Berlin, Germany, Wednesday, Sept. 1, 2021. Credit: AP says Germany is making an initial investment of Photo/Michael Sohn, pool $100 million in the facility.
    [Show full text]
  • (STAG-TB) Members, 2020
    Biographical Profiles of WHO Strategic and Technical Advisory Group for TB (STAG-TB) Members, 2020 STAG-TB Chair • Dr Ariel PABLOS-MÉNDEZ, National of USA and Mexico Professor of Medicine at Columbia University Medical Center, New York, USA Dr Ariel Pablos-Méndez is a physician, scholar, and diplomat in global health. Dr Pablos-Méndez began his public health career at Columbia University working on the emergence of MDR-TB in New York City in the early 1990s; he later led the Global Surveillance Project on Anti-Tuberculosis Drug Resistance at the World Health Organization (WHO). In both instances, his research and publications brought about significant and successful policy changes. He also served as Director of Knowledge Management at WHO in Geneva, creating WHO Press, working to bridge the know-do gap in public health and pioneering global e-Health. As program officer of The Rockefeller Foundation, Dr Pablos-Méndez spearheaded public-private partnerships in R&D for diseases of poverty (e.g. the Global Alliance for TB Drug Development which recently received FDA approval for Pretomanid), the Foundation's strategy on AIDS treatment in Africa, and the Joint Learning Initiative on Human Resources for Health. He returned to Rockefeller as Managing Director and led the Foundation’s initiative to position universal health coverage on the international agenda. Dr Pablos-Méndez was appointed by President Barack Obama, to lead the Global Health program of USAID, serving as Assistant Administrator for Global Health.. Dr Pablos-Méndez drove the vision to End Preventable Child and Maternal Deaths and contributed to catalysing an AIDS-Free Generation while supporting health systems strengthening, family planning and country ownership through initiatives such as The Global Financing Facility for Every Woman Every Child.
    [Show full text]
  • Slew of Trials Launch to Test Coronavirus Treatments In
    began in China. Those studies should be completed by the end of April, and remdesivir could be approved by Chinese authorities as early as May, says Shibo Jiang, a virologist at Fudan University in Shanghai. “But the epidemic might be gone by then,” he says. Researchers in China have also launched a few trials that test chloroquine, a malaria drug that killed off the new coronavirus (recently named SARS-CoV-2) in cell culture4. And scientists are studying whether ster- oids diminish inflammation in people with severe COVID-19, or cause harm. “It will be interesting to see these results,” says Yazdan Yazdanpanah, an epidemiologist with France’s national health agency, INSERM, in Paris. Research clinicians around the world will need this information if the outbreak continues to spread, he adds. Another study — a 300-person controlled trial — will test serum from COVID-19 survivors. FEATURE CHINA/BARCROFT MEDIA VIA GETTY CHINA/BARCROFT FEATURE The same basic idea — that the antibodies one Medics check on people with COVID-19 in Jinyintan Hospital in Wuhan, China. person steadily builds up to fight a virus can help someone freshly infected to fight it off rapidly — has had modest success when used to treat other viruses in the past5. SLEW OF TRIALS LAUNCH Two stem-cell trials are also listed in China’s registry. In one, a team at the First Affiliated TO TEST CORONAVIRUS Hospital of Zhejiang University will infuse 28 people with stem cells derived from men- TREATMENTS IN CHINA strual blood, and compare results with those from people who did not receive the infusions.
    [Show full text]
  • 1St International Conference on Public Health in Africa (CPHIA2021)
    ST INTERNATIONAL CONFERENCE ON 1 PUBLIC HEALTH IN AFRICA CPHIA2021 COVID-19 IN AFRICA: ONE YEAR LATER ADDIS ABABA, ETHIOPIA | 12–14 MAY 2021 The SARS-CoV-2 virus that causes the coronavirus disease (COVID-19) was first reported in December 2019 in China. It has infected over 19 million CONFERENCE FORMAT people and caused more than 700,000 deaths globally. The COVID-19 PARTICIPATORY SESSIONS, including roundtable pandemic has negatively impacted endemic disease programmes in discussions, debates, symposia, ‘fishbowl’/panel Africa, including HIV/AIDS, tuberculosis, malaria, routine immunization, and discussions, and other forms of interaction that encourage non-communicable diseases. It has contributed to severe food insecurity, active audience participation using a virtual format. gender-based violence and economic slowdown as well as disruption of Africa’s Continental Free Trade Area agreement. The First International PANEL PRESENTATIONS, using traditional panel Conference on Public Health in Africa, organized by Africa CDC, will presentation sessions, oral and poster abstract focus on COVID-19 in Africa: one year later and allow a review of lessons presentations and audience discussion and interaction. learned from the COVID-19 pandemic and opportunities to re-evaluate the new normal in public health practice in Africa. ORGANIZING COMMITTEE CONFERENCE TRACKS John Nkengasong, Africa Centres of Disease Control and Prevention (Africa CDC), Addis PhD (Chair) Ababa, Ethiopia Day 1: Exploring the Science of COVID-19 Salim S. Abdool Karim,
    [Show full text]
  • 2021 GTFCC World Health Assembly Side Event 20 May 2021 Biographies: Speakers and Moderators
    2021 GTFCC World Health Assembly Side Event 20 May 2021 Biographies: Speakers and Moderators 1 Biographies: Table of Contents Dr. Tedros Adhanom Ghebreyesus..................................................................................... 3 Dr. Frew Benson ............................................................................................................... 4 Dr. Seth Berkley ............................................................................................................... 5 Dr. Christopher R. Braden.................................................................................................. 6 Dr. Godfrey Bwire ............................................................................................................. 7 Mr. Emanuele Capobianco ................................................................................................ 8 Ms. Simone Carter ............................................................................................................ 9 Mr. Wiseman Chimwaza ................................................................................................. 10 Ms. Pamela Mwelala Chisanga ....................................................................................... 11 Dr. Marc Gastellu-Etchegorry .......................................................................................... 12 Christine Marie George, PhD ........................................................................................... 13 Dr. Myriam Henkens ......................................................................................................
    [Show full text]
  • AFRICA's LEADERSHIP in COVID-19 VACCINE DEVELOPMENT and ACCESS Virtual Conference
    AFRICA'S LEADERSHIP IN COVID-19 VACCINE DEVELOPMENT AND ACCESS Virtual Conference Wednesday 24 June | 2:00 PM EAT Thursday 25 June | 1:00 PM EAT Africa's Leadership in COVID-19 Vaccine Development and Access SCHEDULE SESSION PROGRAMME SPEAKERS (EAT) MODERATOR HE Amira Elfadil Mohammed Elfadil Introduction Commissioner for Social Affairs, African Union Commission, 2:00 - 2:05 PM Ethiopia Welcome Remarks HE Moussa Faki Mahamat 2:05 - 2:10 PM Chairperson, African Union Commission, Ethiopia SESSION I 2:00 - 2:45 PM Opening State of Pandemic Globally Dr Tedros Ghebreyesus 2:10 - 2:25 PM Director-General, World Health Organisation, Geneva Opening Remarks HE President Matamela Cyril Ramaphosa 2:25 - 2:30 PM Chairperson, African Union and President, Republic of South Africa The Need for Africa’s Leadership in Dr John Nkengasong COVID-19 Vaccines and Development Director, Africa Centres for Disease Control and Prevention, 2:30 - 2:45 PM Ethiopia 2:45 - 2:50 PM TECHNICAL TRANSITION TO SESSION II CO-MODERATORS Prof Samba Ousmane Sow Director General, Center for the Development of Vaccines in Mali, Introduction to Session II Ministry of Health, Mali 2:50 - 2:55 PM SESSION II Prof Lynn Morris COVID-19 Vaccines Interim Director, National Institute for Communicable Diseases, 2:50 - 4:00 PM Development and Republic of South Africa Clinical Trials Needs and Requirements of Candidate Prof Salim Abdool Karim Vaccines Clinical Trials in Africa Chair of the South African Ministerial Advisory Committee for WEDNESDAY 2:55 - 3:05 PM COVID-19, Republic of South
    [Show full text]
  • Role of Nphis in Re-Emerging Infectious Diseases Dr. Chikwe
    Nigeria Centre for Disease Control Protecting the health of Nigerians Role of NPHIs in Re-Emerging Infectious Diseases Lassa fever: The Nigerian Experience Dr. Chikwe Ihekweazu Director General Mandatory disclosure slide No conflict of interest 2 NIGERIA CENTRE FOR DISEASE CONTROL Nigeria’s health and economy Population ~ 186 million Annual population growth rate of 2.6% Recent outbreaks - Lassa fever, Ebola, Monkeypox, Yellow fever, Meningitis Low expenditure on health as a percentage of GDP Multiple competing priorities for Government 3 NIGERIA CENTRE FOR DISEASE CONTROL 3 Major outbreaks in Nigeria 4 NIGERIA CENTRE FOR DISEASE CONTROL Lassa fever in Nigeria Large outbreak in 2018 Ongoing outbreak in 2019 638 confirmed cases 420 confirmed cases 171 deaths 93 deaths 23/36 states affected 21/36 states affected Case fatality: 26% Case fatality: 22% Cases concentrated in three hotspot Cases being detected in new states states 5 NIGERIA CENTRE FOR DISEASE CONTROL Trends of Lassa fever in Nigeria (2016-2019) 6 NIGERIA CENTRE FOR DISEASE CONTROL 7 NIGERIA CENTRE FOR DISEASE CONTROL Improved digital surveillance WHO, ECOWAS, R-CDC Aggregated monthly Nigeria Centre for Disease Control CDC Aggregated weekly (by Wednesday) State/Regional Health Department Aggregated weekly (by Tuesday) District / Local Government Area Health Dpt. Aggregated weekly (by Monday) Local Health Care Facilities 8 NIGERIA CENTRE FOR DISEASE CONTROL Improved digital surveillance WHO, ECOWAS, R-CDC Aggregated monthly Nigeria Centre for Disease Control CDC manual data entry
    [Show full text]
  • The Nigeria CDC
    Insights From Africa’s Covid-19 Response: The Nigeria CDC DAVID CRONE Contents Summary 3 The Role of the Nigeria CDC 4 Communicating Key Messages 5 Institutional Collaboration 6 Learning for the Future 7 Published at https://institute.global/advisory/insights-africas- covid-19-response-nigeria-cdc on December 10 2020 Summary The Nigeria Centre for Disease Control (Nigeria CDC) was at the heart of the federal Covid-19 response in Africa’s most populous country. It worked closely with a number of institutions, and its director has been clear about the challenges it has faced and his determination to build a more SUMMARY SUMMARY sustainable public-health infrastructure for the future. 3 The Role of the Nigeria CDC With the largest total population and highest proportion of residents living in urban areas of any country THE ROLE OF NIGERIA CDC THE ROLE OF NIGERIA CDC in Africa, Nigeria was at particular risk of extensive spread of Covid-19. 1 Its vast size, federal system of government and the need to respond simultaneously to outbreaks of Lassa fever and measles alongside Covid-19 had the potential to inhibit the speed and coherence of the pandemic response. TBI analysis of data from the Oxford Covid-19 Government Response Tracker suggests that Nigeria was one of the first sub-Saharan African countries to introduce measures to address the pandemic after the disease was confirmed to have spread beyond Asia: The Nigeria CDC established a Technical Working Group that would later evolve into the Emergency Operations Centre, and developed an incident action plan, trained staff, repurposed existing PCR testing capacity and issued guidance before Nigeria’s first case was confirmed on 25 ebruarF y.
    [Show full text]
  • Disease Surveillance for the COVID-19 Era: Time for Bold Changes
    Comment the reduction of cardiovascular disease burden in 5 Bukhman G, Mocumbi AO, Atun R, et al. The Lancet NCDI Poverty Commission: bridging a gap in universal health coverage for the poorest women worldwide. The Commission’s recommendations billion. Lancet 2020; 396: 991–1044. on additional funding for women’s cardiovascular 6 Bassig BA, Dean Hosgood H, Shu XO, et al. Ischaemic heart disease and stroke mortality by specific coal type among non-smoking women with health programmes, prioritisation of integrated care substantial indoor air pollution exposure in China. Int J Epidemiol 2020; programmes, including combined cardiac and obstetric 49: 56–68. 7 Stewart S, Mocumbi AO, Carrington MJ, Pretorius S, Burton R, Sliwa K. care, and strengthening of the health systems accords A not-so-rare form of heart failure in urban black Africans: pathways to right 5 heart failure in the Heart of Soweto Study cohort. Eur J Heart Fail 2011; with efforts to bridge the gap for the world’s worst off. 13: 1070–77. Such a shift in women’s cardiovascular care would be a 8 Mocumbi AO, Sliwa K. Women’s cardiovascular health in Africa. Heart 2012; 98: 450–55. major step towards equity, social justice, and sustainable 9 Zühlke L, Engel ME, Karthikeyan G, et al. Characteristics, complications, and development. gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J 2015; I declare no competing interests. 36: 1115–22a. 10 WHO. Maternal mortality, key facts. 2019. https://www.who.int/news-room/ Ana Olga Mocumbi fact-sheets/detail/maternal-mortality (accessed April 24, 2021).
    [Show full text]
  • Biographies IHR Emergency Committee for COVID-19
    Biographies IHR Emergency Committee for COVID-19 CHAIR Professor Didier HOUSSIN President, AP-HP International, the subsidiary of Assistance Publique-Hôpitaux de Paris, Paris, France Professor Didier Houssin is presently the president of AP-HP International, the subsidiary of Assistance Publique - Hôpitaux de Paris (AP-HP) (Greater Paris University Hospitals). Professor of surgery and liver transplant specialist at Paris-Descartes University since 1988, Didier Houssin served as head of surgery at Cochin hospital in Paris, then as executive director of the French transplant agency and, later, as medical policy director of Assistance Publique - Hôpitaux de Paris and vice-president of Paris-Descartes University. From 2005 to 2011, he was director general for health at the French Ministry of health and inter- ministerial delegate for pandemic flu preparedness. President of the French agency for the evaluation of research and higher education (AERES, then HCERES), from 2011 to 2015, and president of the management board of the French agency for food, environmental and occupational health and safety (ANSES) from 2013 to 2016, he served also as an advisor to the World Health Organization since 2011. At the World Health Organization, he was chair of the Pandemic Influenza Preparedness Framework Agreement Advisory Group and, later, chair of the Review Committee on the Role of the International Health Regulations (2005) in the Ebola Outbreak and Response. He is a member of the management board of the European Food Safety Authority (EFSA) and a member of the French National Academy of Medicine. MEMBERS Professor Stuart D. BLACKSELL* Senior Research Scientist, Center for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom of Great Britain and Northern Ireland Professor Stuart Blacksell is a Senior Research Scientist at the University of Oxford based at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) in Thailand where he has been since 2001.
    [Show full text]
  • Human Monkeypox – Epidemiological and Clinical Characteristics, Diagnosis and Prevention
    1 Chapter/Review 12 Clinical Review for IDCNA IDC 33.4 Emerging and Re-Emerging Infectious Diseases Title: Human Monkeypox – Epidemiological and Clinical characteristics, Diagnosis and Prevention Authors*: Eskild Petersen, Anu Kantele, Marion Koopmans, Danny Asogun, Adesola Ogunlete, Chikwe Ihekweazu and Alimuddin Zumla (* All authors contributed equally) Institutional affiliations: Eskild Petersen: Institute of Clinical Medicine, University of Aarhus, Denmark and The Royal Hospital, Muscat, Oman. European Society for Clinical Microbiology and Infectious Diseases Task Force for Emerging Infections, Basel, Switzerland. Email: [email protected] Anu Kantele: Inflammation Center, Helsinki University Hospital and Helsinki University, Helsinki, Finland. Email: [email protected] Marion Koopmans: Viroscience Department, Erasmus Medical Centre, Rotterdam, The Netherlands. Email: [email protected] Danny Asogun: Department of Public Health, Faculty of Clinical Sciences, College of Medicine, Ambrose Alli University, Ekpoma, Nigeria. Email: [email protected] Adesola Ogunleye: Nigeria Centre for Disease Control, Jabi, Abuja, Nigeria. Email: [email protected] Chikwe Ihekweazu: Nigeria Centre for Disease Control, Jabi, Abuja, Nigeria. Email: [email protected] Alimuddin Zumla: Division of Infection and Immunity, Center for Clinical Microbiology, University College London, and the National Institute of Health Research Biomedical Research Centre at UCL Hospitals, London, UK. Email. [email protected] Mailing Addresses:
    [Show full text]
  • Forum on Microbial Threats
    Organized by the Forum on Microbial Threats MOVING PAST COVID-19: LESSONS LEARNED FROM RESPONSES AROUND THE WORLD – SYNDEMICS WEBINAR A VIRTUAL WORKSHOP March 17, 2021 TABLE OF CONTENTS About the Forum ..................................................................................................... Pg. 02 Overview Agenda ................................................................................................................... Pg. 06 Planning Committee ............................................................................................... Pg. 08 Speakers and Participants ....................................................................................... Pg. 13 Suggested Further Reading .................................................................................... Pg. 14 Upcoming Activities ................................................................................................ Pg. 15 1 HEALTH AND MEDICINE DIVISION BOARD ON GLOBAL HEALTH THE FORUM ON MICROBIALTHREATS ---- An Overview ---- ABOUT THE FORUM The Forum on Microbial Threats of the National Academies of Sciences, Engineering, and Medicine (National Academies) was created in 1996 at the request of the Centers for Disease Control and Prevention and the National Institutes of Health to provide a structured opportunity for discussion and scrutiny of critical, and possibly contentious, scientific and policy issues related to research on and the prevention, detection, surveillance, and responses to emerging and reemerging infectious diseases in
    [Show full text]